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Fatal Algaemia in 
Patient with Chronic   
Lymphocytic  
Leukemia
To  the  Editor:  Prototheca  spe-
cies  are  achlorophyllic  lower  algae, 
ubiquitous in nature, which can cause 
human infections, particularly in im-
munocompromised  patients  (1).  Hu-
man protothecosis is mostly caused by 
P. wickerhamii and P. zopfii. Although 
such  infections  are  infrequent,  they 
can  manifest  themselves  clinically 
as  cutaneous  lesions,  olecranon  bur-
sitis,  and,  even  more  rarely,  as  dis-
seminated or systemic infections (1). 
These  infections  occur  in  severely 
immunocompromised  patients,  such 
as persons with AIDS, or patients un-
dergoing extensive treatment, such as 
cancer treatment or organ transplanta-
tion (1–4). We describe a fatal case of 
P. wickerhamii algaemia in a patient 
with chronic lymphocytic leukemia.
In July 2007, a 79-year-old man, 
who had been monitored since 1993 
for stage C chronic lymphocytic leuke-
mia (5), was hospitalized July 13–20 
for a depressive syndrome with fever, 
asthenia, and weight loss (3 kg over 2 
months).  Blood  and  urinary  cultures 
on admission were sterile. The patient 
was hospitalized again on July 30 for 
fever (39°C), anorexia, and diarrhea, 
with ≈7 stools per day. He had lost 10 
kg in 2 weeks. Blood cultures for bac-
teria (in BD Bactec Plus Aerobic/F and 
BD  Bactec  Lytic  Anaerobic/F  vials; 
Becton Dickinson, Le Pont de Claix, 
France) and fungi (BD Bactec Mycosis 
IC/F; Becton Dickinson) and stool cul-
tures for bacteria were negative. Blood 
cultures  were  incubated  in  a  Bactec 
9240 instrument (Becton Dickinson). 
Aspergillus fumigatus was found in a 
bronchoalveolar lavage specimen, but 
no Aspergillus galactomannan antigen 
was detected in blood.
The  patient  was  treated  with 
piperacillin-tazobactam,  ciprofloxa-
cin, acyclovir, voriconazole, and lop-
eramide. Voriconazole  (400  mg/day) 
was used from day 17 to day 27. On 
day 21, Cryptosporidium parvum was 
detected on parasitologic stool exami-
nation.  Symptoms  persisted  on  day 
26, with strong asthenia and deteriora-
tion of general state. At that time, the 
leukocyte count was 178 × 109/L with 
3.56 × 109/L polymorphonuclear neu-
trophils and 172 × 109/L lymphocytes. 
Three peripheral blood samples were 
cultured for detection of bacteria and 
fungi. On day 27, septic shock devel-
oped in the patient. A  blood culture 
showed an Escherichia coli strain sus-
ceptible  to  piperacillin-tazobactam, 
aminoglycosides,  and  quinolones. 
Amikacin was added to the treatment 
regimen. Nonetheless, the patient died 
on day 28.
Two  blood  cultures  for  bacteria 
in aerobic vials grew the day of the 
patient’s death, but tests of blood cul-
tures  for  fungus  remained  negative. 
After  Gram  staining,  gram-positive 
spherical  unicellular  organisms  were 
observed (Figure). After 48 hours of 
incubation,  creamy,  yeast-like  colo-
nies  grew  on  chocolate  agar  (bio-
Mérieux, Marcy l’Etoile, France), but 
not on Sabouraud agar containing gen-
tamicin and chloramphenicol (Becton 
Dickinson). Microscopy and the API 
20C AUX system (bioMérieux) iden-
tified P. wickerhamii.
Sequencing  the  18S  rDNA  with   
the  primers  Pw18SF  5′-TCAAAAA 
GTCCCGGCTAATCTCGTGC-3′   
and Pw18SR 5′-CGCTTTCGTGCCT 
CAATGTCAGTGTT-3′ confirmed the   
identification.  The  sequence  of  the 
amplified product was compared with 
sequences  published  in  the  database 
of  the  National  Center  for  Biotech-
nology  Information  (Bethesda,  MD, 
USA). The most likely identification, 
according to BLAST analysis (www.
ncbi.nlm.nih.gov/blast/Blast.cgi), was 
P. wickerhamii.
In vitro susceptibility tests were 
performed by the Etest method (AB 
Biodisk,  Solna,  Sweden),  on  RPMI 
agar. P. wickerhamii was found to be 
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susceptible  to  amphotericin  B  and 
posaconazole,  with  MICs  of  0.047 
μg/mL  and  0.012  μg/mL,  respec-
tively.  By  contrast,  it  was  resistant 
to  fluconazole  (MIC>256  μg/mL), 
voriconazole  (MIC>32  μg/mL),  and 
caspofungin (MIC>32 μg/mL). It was 
also susceptible to gentamicin (MIC = 
0.25 μg/mL) but resistant to amikacin 
(MIC>24 μg/mL).
However, the patient died before 
the algae were detected in the blood 
culture vials. In this case, antifungal 
treatment based on voriconazole use 
was  empiric  and  ineffective.  Some 
authors  have  described  a  successful 
treatment  on  localized  protothecosis 
with  voriconazole  (6). Amphotericin 
B currently seems to be most effective 
agent, although the best treatment re-
mains a matter of debate (1,4,7). Al-
though in vitro susceptibility test re-
sults are not necessarily well correlated 
with results obtained in vivo, the low 
MIC  of  posaconazole  reported  here 
may be of interest in clinical practice 
(8). In the laboratory, use of selective 
yeast media, such as Sabouraud plus 
gentamicin, or Mycosis IC/F vials for 
blood culture, which contain chloram-
phenicol and tobramycin, may make 
it difficult to detect Prototheca spp., 
which are susceptible to these antimi-
crobial drugs.
In  patients  with  algaemia, Pro-
totheca spp. are often associated with 
bacteria,  viruses,  or  yeasts  which 
cause  co-infections  (1),  as  in  this 
case, in which the alga was associ-
ated with E. coli. This association is 
probably  the  result  of  disseminated 
protothecosis  in  severely  immuno-
compromised  patients,  and  the  alga 
may  cross  digestive  or  cutaneous 
barriers. Reasons for septic shock or 
death  are  unclear  for  most  associa-
tions of pathogens (2,4). Prototheca 
spp. are found in various reservoirs, 
including the environment, animals, 
and food (1). In the case described 
here, the infection may have originat-
ed from a contaminated well used to 
obtain water for the patient’s kitchen 
garden. However, we were unable to 
test this hypothesis.
Disseminated  protothecosis  is 
currently rare but, due to the algae’s 
ubiquitous  nature,  increasing  use  of 
immunosuppressive  therapy,  and  in-
creasing incidence of hematologic ma-
lignancy, Prototheca spp. may emerge 
as opportunistic pathogens. Prototheca   
spp. should also be considered as an 
emerging cause of systemic infection 
in immunocompromised patients.
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Figure.	Gram-positive	spherical	unicellular	organisms	in	a	blood	culture	from	a	79-year-old	
man	with	chronic	lymphocytic	leukemia.	Magnification	×1,000.	A	color	version	of	this	figure	
is	available	online	(www.cdc.gov/EID/content/15/7/1129-F.htm).